RECRUITING

Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The project is a placebo-controlled study that aims to use closed-loop transcranial alternating current stimulation (tACS) to study patients with symptoms of mild cognitive impairment which is likely due to Alzheimer's disease or another form of dementia (AD-MCI). Patients will undergo an EEG and complete some questionnaires and computer tasks during each study visit. The project has the following aims and hypotheses: 1.) To determine the impact of closed-loop 40 Hz tACS on the entrainment of natural gamma rhythms in patients with AD-MCI, 2.) To determine the impact of closed-loop 40 Hz tACS on cognitive performance in patients with AD-MCI, and 3.) To assess the relationship between baseline neurodegenerative burden and impact of tACS. \[exploratory\]

Official Title

Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

Quick Facts

Study Start:2025-01-31
Study Completion:2026-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05904132

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Overall cognitive functional status consistent with amnesic MCI (CDR 0.5) likely due to AD (AD biomarker supported)
  2. * 50-80 years of age
  3. * English native speakers
  1. * Known presence of a structural brain lesion (e.g., tumor, cortical infarct)
  2. * Acute or decompensated active medical conditions, including cancer, cardiovascular disease, stroke, congestive heart failure
  3. * Active hematological, renal, pulmonary, endocrine or hepatic disorders
  4. * Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
  5. * tACS contraindications (lesions in the scalp, history of seizures)

Contacts and Locations

Study Contact

DNN Inbox
CONTACT
6177265348
mghdnn@mgh.harvard.edu

Principal Investigator

Joan Camprodon, MD, PhD, MPH
PRINCIPAL_INVESTIGATOR
MGH, Division of Neuropsychiatry and Neuromodulation

Study Locations (Sites)

Massachusetts General Hospital
Charlestown, Massachusetts, 02129
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Joan Camprodon, MD, PhD, MPH, PRINCIPAL_INVESTIGATOR, MGH, Division of Neuropsychiatry and Neuromodulation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-31
Study Completion Date2026-06

Study Record Updates

Study Start Date2025-01-31
Study Completion Date2026-06

Terms related to this study

Additional Relevant MeSH Terms

  • Alzheimer Disease
  • Mild Cognitive Impairment